Donald Edward Tsai

faculty photo
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania, Philadelphia, PA
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-156
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-615-6506
Fax: 215-615-5887
A.B. (Biochemistry)
Harvard College, Cambridge, MA, 1986.
Ph.D. (Microbiology & Immunology)
Duke University, Durham, NC, 1993.
M.D. (Medicine)
Duke University School of Medicine, Durham, NC, 1994.
Permanent link

Description of Research Expertise

Posttransplant Lymphoproliferative Disorder

Description of Itmat Expertise

Dr. Tsai is interested in new targeted molecular agents for hematology.

Selected Publications

Kremer B, Tsai DE, Debonera F, Cohen P, Schuster SJ. : Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide. Leuk Lymphoma 11: 1-3, 2017 Notes: accepted.

Debonera F, Nasta S, Martinez-Lage M, Schuster SJ, Tsai DE. : Primary diffuse large B-cell lymphoma of the central nervous system: A rare case of spontaneous remission. Int J Hematol Oncol 2017 Notes: accepted.

Nagle SJ, Shah NN, Ganetsky A, Landsburg DJ, Nasta SD, Mato A, Schuster SJ, Reshef R, Tsai DE, Svoboda J. : Long term outcomes of rituximab, temozolomide, and high-dose methotrexate without consolidation therapy for lymphoma involving the central nervous system. Int J Hematol Oncol 2017 Notes: accepted.

Tsai DE, Luskin MR, Kremer BE, Chung AK, Arnoldi S, Paralkar VR, Nasta SD, Stadtmauer EA, Schuster SJ, Xavier M. : A pilot trial of quantitative EBV PCR in patients undergoing treatment for their malignancy: potential use of EBV PCR in multiple cancer types. Leukemia & Lymphoma 56: 1530-1532, 2015.

Paul TM, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Nasta SD, Loren A, Frey N, Perl A, Cohen AD, Weiss BM, Stadtmauer EA, Vogl DT. : Outpatient autologous stem cell transplantation for patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 15: 536-540, 2015.

Luskin MR, Heil DS, Tan KS, Choi S, Stadtmauer EA, Schuster SJ, Porter DL, Vonderheide RH, Bagg A, Heitjan DF, Tsai DE, Reshef R. : The impact of EBV status on characteristics and outcomes of Posttransplant lymphoproliferative disorder. Am J Transplant 15: 2665-2673, 2015.

Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O, Bennett CL. : Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 120: 2464-2471, 2014.

Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM, Payne AS : Subcutaneous veltuzumab, a humanized anti-CD20 antibody, for treatment of refractory pemphigus vulgaris. JAMA Dermatology 150: 1331-1335, 2014.

Karuturi M, Shah N, Frank D, Fasan O, Reshef R, Ahya VN, Bromberg M, Faust T, Goral S, Schuster SJ, Stadtmauer EA, Tsai DE: Plasmacytic Posttransplant lymphoproliferative disorder: a case series of nine patients. Transplant International 26: 616-622, 2013.

Landsburg DJ, Stadtmauer E, Loren A, Goldstein S, Frey N, Nasta SD, Porter DL, Tsai DE, Perl AE, Hexner EO, Luger S: Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens. American Journal of Hematology 88: 657-660, 2013.

back to top
Last updated: 11/29/2017
The Trustees of the University of Pennsylvania